Clinical trials: BRCA Mutated
Pancreatic Ductal Adenocarcinoma
A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma
The purpose of this study is to better understand why pancreatic cancer develops in some people who are known carriers of the gene mutation (an abnormality) called BRCA, or its close relative PALB2.
- Trial name
- NCT01983410
- Testing
- The risk assessment questionnaire, Blood specimens, tumor tissue samples will be requested
- Where
- 13 sites in United States, Israel
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
brca1 Mutation Carrier, brca2 Mutation Carrier
Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
- Trial name
- NCT00321633
- Testing
- carboplatin, docetaxel
- Where
- 25 sites in Australia, Israel and 4 more
- Volunteers
- 148 people
- Sponsor
- University College London Hospitals
Breast Cancer
Lynparza Breast Cancer Clinical Experience Investigation
To characterise the development of ADRs of bone marrow depression in patients under actual post-marketing use
- Trial name
- NCT03590938
- Where
- 31 sites in Japan
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Breast Cancer
Women At Risk: The High Risk Breast Cancer Program
The purpose of this study is to increase understanding of women who are at high risk for developing breast cancer. Data from this group will be collected and entered into a registry.
- Trial name
- WAR (NCT01034891)
- Where
- 2 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- New York Presbyterian Hospital
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Cancer Prevention in Women With a BRCA Mutation
This study aims to develop a follow-up telephone-based genetic counselling (FTGC) intervention for women with a BRCA1 or BRCA2 mutation who have received genetic counseling in the past.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Cancer, Ovarian Cancer
- Trial name
- NCT02225015
- Testing
- Follow-up Telephone Genetic Counselling
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- Women's College Hospital
Advanced Solid Tumors, HRD
Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors
This is an open-label, dose-escalation/dose-expansion, phase I clinical trial study to investigate the safety, tolerability, and efficacy of HWH340. In addition, the pharmacokinetic characteristics will also be investigated.
- Conditions
- Advanced Solid Tumors, HRD, BRCA Mutation
- Trial name
- NCT03415659
- Testing
- HWH340 tablet
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Hubei Biological Medicine Industrial Technology Institute Co., Ltd.